Covered recipient · General Payments record
ALBERT J WEISBROT
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2023
$5,011.82
- Reported across 151 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $170.06 | 10 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $103.42 | 6 |
| Xeris Pharmaceuticals, Inc. | $20.12 | 1 |
| Lilly USA, LLC | $16.80 | 1 |
| Exact Sciences Corporation | $15.52 | 1 |
| Acerta Pharma LLC | $14.20 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $14.20 | 04/06/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1015920515 | CMS |
| Exact Sciences Corporation | $15.52 | 02/16/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1026617895 | CMS |
| Lilly USA, LLC | $16.80 | 03/24/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1031235911 | CMS |
| Novo Nordisk Inc | $17.83 | 04/14/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000695923 | CMS |
| Novo Nordisk Inc | $17.73 | 04/19/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000695913 | CMS |
| Novo Nordisk Inc | $15.34 | 04/27/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000695893 | CMS |
| Novo Nordisk Inc | $19.04 | 05/18/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000695943 | CMS |
| Novo Nordisk Inc | $17.98 | 06/09/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000695933 | CMS |
| Novo Nordisk Inc | $15.50 | 06/22/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1000695903 | CMS |
| Xeris Pharmaceuticals, Inc. | $20.12 | 03/30/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1056436497 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.